• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    12/11/23 12:35:24 PM ET
    $BLUE
    $CERE
    $CI
    $CVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLUE alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    LLY CALL SWEEP BEARISH 12/15/23 $600.00 $27.8K 3.3K 6.1K
    CVS PUT SWEEP BEARISH 12/15/23 $72.50 $30.0K 752 3.0K
    NRIX CALL TRADE BEARISH 12/15/23 $7.50 $200.0K 3.3K 2.0K
    GILD CALL SWEEP BULLISH 12/15/23 $80.00 $68.6K 7.3K 1.3K
    BLUE CALL SWEEP BULLISH 01/19/24 $2.50 $47.4K 11.3K 1.0K
    CERE CALL TRADE BULLISH 01/19/24 $35.00 $227.1K 1.0K 501
    TGTX CALL SWEEP BEARISH 01/19/24 $16.00 $33.0K 1.8K 218
    SAVA CALL TRADE BULLISH 01/12/24 $27.00 $27.5K 1 203
    CI PUT TRADE BULLISH 01/17/25 $250.00 $77.2K 416 114
    IMGN CALL TRADE BULLISH 04/19/24 $17.00 $94.5K 1.0K 75

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For LLY (NYSE:LLY), we notice a call option sweep that happens to be bearish, expiring in 4 day(s) on December 15, 2023. This event was a transfer of 174 contract(s) at a $600.00 strike. This particular call needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $160.0 per contract. There were 3367 open contracts at this strike prior to today, and today 6182 contract(s) were bought and sold.

    • Regarding CVS (NYSE:CVS), we observe a put option sweep with bearish sentiment. It expires in 4 day(s) on December 15, 2023. Parties traded 1000 contract(s) at a $72.50 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $30.0 per contract. There were 752 open contracts at this strike prior to today, and today 3031 contract(s) were bought and sold.

    • For NRIX (NASDAQ:NRIX), we notice a call option trade that happens to be bearish, expiring in 4 day(s) on December 15, 2023. This event was a transfer of 2000 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $200.0K, with a price of $100.0 per contract. There were 3317 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold.

    • Regarding GILD (NASDAQ:GILD), we observe a call option sweep with bullish sentiment. It expires in 4 day(s) on December 15, 2023. Parties traded 1202 contract(s) at a $80.00 strike. This particular call needed to be split into 49 different trades to become filled. The total cost received by the writing party (or parties) was $68.6K, with a price of $57.0 per contract. There were 7371 open contracts at this strike prior to today, and today 1331 contract(s) were bought and sold.

    • For BLUE (NASDAQ:BLUE), we notice a call option sweep that happens to be bullish, expiring in 39 day(s) on January 19, 2024. This event was a transfer of 496 contract(s) at a $2.50 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $47.4K, with a price of $95.0 per contract. There were 11314 open contracts at this strike prior to today, and today 1093 contract(s) were bought and sold.

    • Regarding CERE (NASDAQ:CERE), we observe a call option trade with bullish sentiment. It expires in 39 day(s) on January 19, 2024. Parties traded 350 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $227.1K, with a price of $649.0 per contract. There were 1083 open contracts at this strike prior to today, and today 501 contract(s) were bought and sold.

    • For TGTX (NASDAQ:TGTX), we notice a call option sweep that happens to be bearish, expiring in 39 day(s) on January 19, 2024. This event was a transfer of 189 contract(s) at a $16.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $33.0K, with a price of $175.0 per contract. There were 1880 open contracts at this strike prior to today, and today 218 contract(s) were bought and sold.

    • Regarding SAVA (NASDAQ:SAVA), we observe a call option trade with bullish sentiment. It expires in 32 day(s) on January 12, 2024. Parties traded 100 contract(s) at a $27.00 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $275.0 per contract. There were 1 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold.

    • For CI (NYSE:CI), we notice a put option trade that happens to be bullish, expiring in 403 day(s) on January 17, 2025. This event was a transfer of 75 contract(s) at a $250.00 strike. The total cost received by the writing party (or parties) was $77.2K, with a price of $1030.0 per contract. There were 416 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold.

    • Regarding IMGN (NASDAQ:IMGN), we observe a call option trade with bullish sentiment. It expires in 130 day(s) on April 19, 2024. Parties traded 75 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $94.5K, with a price of $1260.0 per contract. There were 1054 open contracts at this strike prior to today, and today 75 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BLUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLUE
    $CERE
    $CI
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    3/10/2026$180.00Buy
    Jefferies
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Gilead Sciences Inc.
    $GILD
    1/7/2026$145.00Buy
    UBS
    More analyst ratings

    $BLUE
    $CERE
    $CI
    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Kates Jamie G was granted 814 shares and covered exercise/tax liability with 132 shares, increasing direct ownership by 40% to 2,368 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    3/3/26 7:20:05 PM ET
    $CI
    Medical Specialities
    Health Care

    Officer Neville Everett was granted 5,280 shares, covered exercise/tax liability with 1,400 shares and sold $496,636 worth of shares (1,719 units at $288.91), increasing direct ownership by 62% to 5,670 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    3/3/26 7:18:57 PM ET
    $CI
    Medical Specialities
    Health Care

    EVP, Global CIO Koka Durga Prasad was granted 3,177 shares and covered exercise/tax liability with 220 shares, increasing direct ownership by 68% to 7,281 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    3/3/26 7:19:26 PM ET
    $CI
    Medical Specialities
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Gilead Sciences with a new price target

    Jefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00

    3/10/26 8:40:41 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Health Foundation Invests $2.24 Million to Expand Community‑Based Care Through Health Impact Ohio

    Health Zones effort aims to improve health care access, reduce emergency utilization and support residents with chronic conditionsCOLUMBUS, Ohio, March 10, 2026 /PRNewswire/ --The CVS Health Foundation today announced the launch of its Health Zone in Columbus with a $2.24 million investment in Health Impact Ohio to help improve access to health care, reduce emergency care utilization and support residents with chronic and behavioral health conditions. "Families across the south and east sides of Columbus continue to face significant and interconnected challenges," said Jenny McC

    3/10/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

    New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC

    3/10/26 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

    NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026 annual meeting, being held April 18 - 22, 2026, in Chicago, Illinois. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below. TG PRESENTATIONS: Poster Presentation Title: Real World Clinical Experience from ENABLE, the First Phase 4 Observational Study for Patien

    3/6/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    SEC Filings

    View All

    Cassava Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/10/26 8:15:27 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Nurix Therapeutics Inc.

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    3/6/26 4:40:45 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Nurix Therapeutics Inc.

    424B5 - Nurix Therapeutics, Inc. (0001549595) (Filer)

    3/6/26 4:38:38 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer

    Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of DirectorsEvanko elected to the company's Board of DirectorsCompany reaffirms 2026 Financial OutlookBLOOMFIELD, Conn., March 3, 2026 /PRNewswire/ -- The Cigna Group (NYSE: CI) today announced that David M. Cordani will retire as chief executive officer effective July 1, 2026, and become executive chair of The Cigna Group's Board of Directors. Brian Evanko, current president and chief operating officer, will succeed Cordani as CEO. Throughout his tenure—inclu

    3/3/26 7:30:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VINCENT COUNTRY SAFE ZONE ACTIVITY DAY PRESENTED BY CIGNA HEALTHCARE DELIVERS SUPER BOWL WEEK FUN, NFL FLAG FOOTBALL, AND WELLNESS TO OAKLAND STUDENTS

    Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen

    2/3/26 8:17:00 PM ET
    $CI
    Medical Specialities
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    Financials

    Live finance-specific insights

    View All

    AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI). The majority of Cigna's core U.S. health insurance entities are collectively referred to as Cigna Life & Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IR) of Cigna. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of Cigna. The outlook of these Credit Ratings (ratings) is stable. (

    3/4/26 5:40:00 PM ET
    $CI
    Medical Specialities
    Health Care

    TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

    Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900 million in total global revenue for 2026 Conference call to be held today, Thursday, February 26, 2026, at 8:30 AM ET NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2025, along with recent company developments and 2026 financial guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Off

    2/26/26 7:00:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.

    2/23/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLUE
    $CERE
    $CI
    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

    SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

    11/14/24 4:39:36 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care